Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
NASDAQ:URGN
Price:
18.48
USD
-0.59%
Market Closed
Market Cap:
$865m
Relative Value
The Relative Value of one
URGN
stock under the Base Case scenario is
14.72
USD.
Compared to the current market price of 18.48 USD,
Urogen Pharma Ltd
is
Overvalued by 20%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
URGN
Relative Value
Base Case
14.72
USD
Overvaluation 20%
Multiples Across Competitors
URGN Competitors Multiples
Urogen Pharma Ltd Competitors
Urogen Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Urogen Pharma Ltd
NASDAQ:URGN
|
893.5m USD | 8.1 | -5.8 | -7.2 | -7.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.3B USD | 6 | 88 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.4B USD | 5.2 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 6 | 20.6 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD | 9.6 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.5 | 17.5 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
64.8B AUD | 3 | 32.9 | 11 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.7B EUR | 10.3 | 33.2 | 35.8 | 36.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
